Digy

 

LIT – CP

COMPOSITION

Each 5 ml suspension contains:
Paracetamol IP  ………………………….125 mg
Phenylephrine hydrochloride IP…………5 mg
Chlorpheniramine maleate IP……………1 mg

INDICATIONS

Relief of nasal and sinus congestion.
Relief of allergic symptoms of the nose or throat due to upper respiratory tract allergies.
Relief of sinus pain and headache.
Adjunct with antibacterials in sinusitis, tonsillitis and otitis media.

DOSAGE & ADMINISTRATION

Children: The usual recommended dose is 1-2 teaspoonful (5-10 ml) tid or qid.

DESCRIPTION

LIT CP Suspension  contain a clinically proven analgesic-antipyretic Paracetamol with decongestant Phenylephrine and an antihistamine Chlorpheniramine maleate. Paracetamol produces analgesia by elevation of the pain threshold and antipyretic effect through action on the hypothalamic heat-regulating center.
Sympathomimetic decongestants reduce the nasal congestion due to increased nasal blood flow associated with colds and influenza. Phenylephrine is sympathomimetic vasoconstrictor that has been used as a decongestant. It is a relatively selective alpha-adrenoceptor agonist. The majority of the sympathomimetic action is due to direct stimulation of the adrenoceptors and relatively little is due to an indirect effect via release of noradrenaline. Its pressor action is weaker than that of noradrenaline but of longer duration. At therapeutic doses, it does not cause significant stimulation of the central nervous system.
The pharmacokinetics of this combination of LIT CP Suspension  is well matched and synergistic. All the drugs are well absorbed orally.

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients of the formulation.
Severe hypertension.

PRECAUTIONS

In case a hypersensitivity reaction occurs which is rare, LIT CP Suspension should be discontinued.

LIT CP Suspension  contains Paracetamol and therefore should not be used in conjunction with other Paracetamol containing products.
LIT CP Suspension  should be used with caution in patients with renal or hepatic dysfunction, hyperthyroidism, cardiovascular problems.

DRUG INTERACTIONS

Clinically significant drug interactions may occur on concomitant administration of LIT CP Suspension  with monoamine oxidase inhibitors, tricyclic antidepressants, beta-adrenergic agents, methyldopa, reserpine and veratrum alkaloids.

ADVERSE REACTIONS

LIT CP Suspension  is generally well tolerated and adverse events are rare. Hypersensitive individuals may display ephedrine-like reactions such as tachycardia, palpitations, headache, dizziness and nausea. Use of sympathomimetics has been associated with fear, anxiety, restlessness, tremor,
weakness, dysuria, insomnia, hallucinations and convulsions. Chlorpheniramine in
LIT CP Suspension  may cause sedation.

PRESENTATION

LIT CP  Suspension  is available in bottles of 60 ml  with measuring cup.